Company Quick10K Filing
Quick10K
Invo Bioscience
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
8-K 2019-01-14 Enter Agreement, Other Events, Exhibits
8-K 2018-11-13 Enter Agreement, Other Events, Exhibits
GILD Gilead Sciences 84,090
CYRX Cryoport 467
CATC Cambridge Bancorp 398
UBX Unity Biotechnology 381
CATO Cato 350
LOV Spark Networks Se 175
INUV Inuvo 45
NVLN Novelion Therapeutics 23
NETE Net Element 20
ABAC Renmin Tianli Group 0
IVOB 2019-03-31
Part I. Financial Information
Item 1. Financial Statements
Note 1 - Basis of Presentation
Note 2 - Recent Accounting Pronouncements
Note 3 - Going Concern
Note 4 - Inventory
Note 5 - Property and Equipment
Note 6 - Patents
Note 7 - Notes Payable
Note 8 - Notes Payable and Other Related Party Transactions
Note 9 - Stockholders' Equity
Note 10 - Stock Options and Warrants
Note 11 - Income Taxes
Note 12 - Commitments and Contingencies
Note 13 - Contracts with Customers
Note 14 - Subsequent Events
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risks
Item 4. Controls and Procedures
Item 4A. Evaluation of Disclosure Controls and Procedures
Item 4B. Changes in Internal Control Over Financial Reporting
Part II. Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Issuance of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Reserved
Item 5. Other Information
Item 6. Exhibits
EX-31.1 ex_144560.htm
EX-31.2 ex_144561.htm
EX-32 ex_144563.htm

Invo Bioscience Earnings 2019-03-31

IVOB 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 invobio20190331_10q.htm FORM 10-Q invobio20190331_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549    

 


 

FORM 10-Q

 


 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2019

 

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE

 

Commission file number 333-147330

 

INVO Bioscience, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

 

20-4036208

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

407 Rear Mystic Avenue, Suite 34C, Medford, MA 02155

(Address of principal executive offices, including zip code)

 

 (978) 878-9505

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒  No ☐

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☐

 

Non-accelerated filer ☐

Smaller reporting company ☒

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒

 

Securities registered pursuant to Section 12(b) of the Act:  None.

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
 

Shares of common stock, par value $.0001 per share:  155,421,112 shares outstanding as of May 10, 2019.

 

 

INVO BIOSCIENCE, INC.

FORM 10-Q

FOR THE QUARTER ENDED March 31, 2019

 

TABLE OF CONTENTS

 

Item

 

Page Number

Part I

 

 

 

1.

Financial Statements (Unaudited):

3

 

Condensed Consolidated Balance Sheets as of March 31, 2019 (Unaudited) and December 31, 2018

3

 

Condensed Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018 (Unaudited)

 4

 

Condensed Consolidated Statements of Shareholders’ Deficiency for the three months ended March 31, 2019 and 2018 (unaudited)

5

 

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018 (Unaudited)

6

 

Notes to the Condensed Consolidated Financial Statements (Unaudited)

7

2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

3.

Quantitative and Qualitative Disclosures about Market Risks

21

4.

Controls and Procedures

21

 

Evaluation of Disclosure Controls and Procedures

21

 

Changes in Internal Controls Over Financial Reporting

21

 

 

 

Part II

 

 

 

1.

Legal Proceedings

22

1A.

Risk Factors

23

2.

Unregistered Issuance of Equity Securities and Use of Proceeds

23

3.

Defaults Upon Senior Securities

23

4.

Reserved

23

5.

Other Information

23

6.

Exhibits

23

 

Signatures

24

 

 

PART I.  FINANCIAL INFORMATION

 

Item 1.       Financial Statements

 

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   

March 31,

   

December 31,

 
   

2019

   

2018

 

ASSETS

 

(unaudited)

         

Current assets

               

    Cash

  $ 3,057,466     $ 212,243  

    Accounts receivable net

    74,717       225,899  

    Inventory, net

    51,685       43,513  

    Prepaid expense and other current assets

    226,696       249,454  

      Total current assets

    3,410,564       731,109  
                 

Property and equipment, net

    81,709       34,446  
                 

Other Assets:

               

Capitalized patents, net

    10,958       11,792  

Total other assets

    10,958       11,792  
                 

Total assets

  $ 3,503,231     $ 777,347  
                 

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

               

Current liabilities

               

     Accounts payable and accrued liabilities, including related parties

  $ 588,354     $ 571,828  

     Accrued compensation

    932,661       2,515,256  

     Deferred revenue

    4,840,323       18,895  

     Note payable

    -       131,722  

     Note payable - related party

    35,000       97,743  

     Convertible notes, net of discount

    196,883       157,039  

     Convertible notes, related party - net of discount

    12,480       9,087  

          Total current liabilities

    6,605,701       3,501,570  
                 

Commitments and contingencies

    -       -  
                 

Stockholder's deficiency

               

Preferred Stock, $.0001 par value; 100,000,000 shares authorized;

No shares issued and outstanding as of March 31, 2019 and December 31 2018, respectively

    -       -  

Common Stock, $.0001 par value; 200,000,000 shares authorized; 154,621,112 and 154,292,497

issued and outstanding as of March 31, 2019 and December 31, 2018, respectively

    15,461       15,429  

   Additional paid-in capital

    19,061,861       18,981,570  

   Accumulated deficit

    (22,179,792

)

    (21,721,222

)

      Total stockholder's deficiency

    (3,102,470

)

    (2,724,223

)

                 

Total liabilities and stockholders' deficiency

  $ 3,503,231     $ 777,347  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.  

 

 

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

  

   

For the

   

For the

 
   

Three Months

   

Three Months

 
   

Ended

   

Ended

 
   

March 31,

   

March 31,

 
   

2019

   

2018

 
                 
                 

Revenue

  $ 189,432     $ 104,140  

Cost of Goods Sold:

    10,978       14,424  
                 

Gross Margin

    178,454       89,716  
                 
                 

Selling, general and administrative expenses

    527,565       229,999  

      Total operating expenses

    527,565       229,999  
                 

Loss from operations

    (349,111

)

    (140,283

)

                 

Other (income) expense:

               

Interest expense

    109,459       4,440  

 Total other (income) expenses

    109,459       4,440  
                 

Loss before income taxes

    (458,570

)

    (144,723

)

                 

Provisions for income taxes

    -       -  
                 

Net Loss

  $ (458,570

)

  $ (144,723

)

                 

Basic net loss per weighted average shares of common stock

  $ (0.00

)

  $ (0.00

)

                 

Diluted net loss per weighted average shares of common stock

  $ (0.00

)

  $ (0.00

)

                 

Basic weighted average number of shares of common stock

    154,102,856       143,340,969  
                 

Diluted weighted average number of shares of common stock

    154,102,856       143,340,969  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

(unaudited)

 

   

Common Stock

                         
   

Shares

   

Amount

   

Additional Paid-in Capital

   

Accumulated Deficit

   

Total

 
                                         

Balance, December 31, 2017

    142,132,374     $ 14,213     $ 13,638,806     $ (18,645,131

)

  $ (4,992,112

)

Common stock issued for cash

    260,000       26       46,974       -       47,000  

Common stock issued to employees

    1,200,000       120       137,880       -       138,000  

Common stock issued for services

    352,326       35       43,629       -       43,664  

Net loss for the three months ended March 31, 2018

    -       -       -       (144,723

)

    (144,723

)

Balance, March 31, 2018 (unaudited)

    143,944,700     $ 14,394     $ 13,867,289     $ (18,789,854

)

  $ (4,908,171

)

                                         
                                         

Balance, December 31, 2018

    154,292,497     $ 15,429     $ 18,981,570     $ (21,721,222

)

  $ (2,724,223

)

Common stock issued for services

    60,000       6       26,594       -       26,600  

Conversion of notes payable and accrued interest

    268,615       26       53,697       -       53,723  

Net loss for the three months ended March 31, 2019

    -       -       -       (458,570

)

    (458,570

)

Balance, March 31, 2019 (unaudited)

    154,621,112     $ 15,461     $ 19,061,861     $ (22,179,792

)

  $ (3,102,470

)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

 

 

 

For the

 

 

For the

 

 

 

Three Months

 

 

Three Months

 

 

 

Ended

 

 

Ended

 

 

 

March 31,

 

 

March 31,

 

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

   Net loss

 

$

(458,570

)

 

$

(144,723

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

 

 

 

 

     Non-cash stock compensation issued for services

 

 

26,600

 

 

 

181,664

 

     Depreciation and amortization

 

 

1,971

 

 

 

1,134

 

     Amortization of discount on notes payable

 

 

93,237

 

 

 

-

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

     Accounts receivable

 

 

151,182

 

 

 

(24,160

)

   Inventories

 

 

(8,172

)

 

 

3,939

 

      Prepaid expenses and other current assets

 

 

22,758

 

 

 

(12,523

)

      Deferred revenue

 

 

4,821,428

 

 

 

-

 

      Accounts payable and accrued expenses

 

 

20,249

 

 

 

(124,884

)

      Accrued compensation

 

 

(1,582,595

)

 

 

82,200

 

   Net cash provided by (used in) operating activities

 

 

3,088,088

 

 

 

(37,353

)

 

 

 

 

 

 

 

 

 

Cash from investing activities:

 

 

 

 

 

 

 

 

    Payments to acquire property, plant and equipment

 

 

(48,400

)

 

 

-

 

Net cash used in investing activities

 

 

(48,400

)

 

 

-

 

 

 

 

 

 

 

 

 

 

Cash from financing activities:

 

 

 

 

 

 

 

 

     Cash paid for related party notes payable

 

 

(62,743

)

 

 

-

 

     Cash paid for notes payable

 

 

(131,722

)

 

 

-

 

     Proceeds from the sale of common stock

 

 

-

 

 

 

47,000

 

Net cash (used in) provided by financing activities

 

 

(194,465

)

 

 

47,000

 

 

 

 

 

 

 

 

 

 

Increase in cash and cash equivalents

 

 

2,845,223

 

 

 

9,647

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

 

212,243

 

 

 

25,759

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

$

3,057,466

 

 

$

35,406

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

 

 

 

Interest

 

$

9,879

 

 

$

-

 

 

 

 

 

 

 

 

 

 

Taxes

 

$

912

 

 

$

912

 

 

 

 

 

 

 

 

 

 

Common stock issued for conversion of notes payable and accrued interest

 

$

53,723

 

 

$

-

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

(unaudited)

 

Note 1 – Basis of Presentation

 

The accompanying unaudited condensed consolidated balance sheets as of March 31, 2019 and December 31, 2018, the condensed consolidated statements of operations, stockholders’ deficiency and cash flows for the three months ended March 31, 2019 and 2018 of INVO Bioscience, Inc. (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year.

 

The preparation of our unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company’s annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2018 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission (SEC).

 

The Company considers events or transactions that have occurred after the unaudited condensed consolidated balance sheet date of March 31, 2019, but prior to the filing of the unaudited condensed consolidated financial statements with the SEC on this Quarterly Report on Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

 

Note 2 – Recent Accounting Pronouncements

 

Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification.

 

The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s consolidated financial position and results of operations.

 

Recently Adopted Accounting Pronouncements 

 

In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement.  The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of the new standard did not have an impact on the Company’s consolidated financial statements. 

 

Note 3 – Going Concern

 

On January 14, 2019, INVO Bioscience entered into a distribution agreement (the “Distribution Agreement”) with Ferring International Center S.A. (“Ferring”) granted to Ferring exclusive licensing rights to sublicense the Company’s INVOcell together with the retention device. Under the terms of the Distribution Agreement, Ferring was obligated to make an initial payment to the Company of $5,000,000 upon satisfaction of certain closing conditions. The Company received the initial $5 million cash payment received upon the execution of the Ferring distribution agreement in January 2019 and as a result believes its cash on hand will be sufficient to fund its current debt obligations, estimated capital expenditures and working capital needs for the next twelve to eighteen months.

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

 (unaudited)

 

Note 4 – Inventory

 

As of March 31, 2019 and December 31, 2018, the Company recorded the following inventory balances:

 

   

March 31,

2019

   

December 31,

2018

 

Work in Process

  $ 42,428     $ 30,689  

Finished Goods

    9,257       12,824  

Total Inventory, net

  $ 51,685     $ 43,513  

 

Note 5 – Property and Equipment

 

The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of March 31, 2019 and December 31, 2018:

 

 

Estimated Useful Life

Molds

3 to 7 years

 

   

March 31,

2019

   

December 31,

2018

 

Manufacturing Equipment- Molds

  $ 118,763     $ 70,363  

Accumulated Depreciation

    (37,054

)

    (35,917

)

Total

  $ 81,709     $ 34,446  

 

During the three months ended March 31, 2018 and 2017 the Company recorded depreciation expense of $1,137 and $0, respectively. The Company began shipping its new retention device in August 2018 which triggered the start of depreciating our retention device mold during the current quarter.

 

Note 6 – Patents

 

As of March 31, 2019 and December 31, 2018, the Company recorded the following patent balances:

 

   

March 31,

2019

   

December 31,

2018

 

Total Patents

  $ 77,743     $ 77,743  

Accumulated Amortization

    (66,785

)

    (65,951

)

Patent costs, net

  $ 10,958     $ 11,792  

 

During the three ended March 31, 2019 and 2018, the Company recorded $834 and $1,134 in amortization expenses respectively.

 

Estimated amortization expense as of March 31, 2019 is as follows:

 

Years ended December 31,

       

2019

  $ 4,536  

2020

    1,809  

2021

    1,809  

2022 and thereafter

    2,804  

Total

  $ 10,958  

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

 (unaudited)

 

Note 7 – Notes Payable

 

Notes Payable

 

In August 2016, INVO Bioscience converted a long time vendor’s outstanding accounts payable balance of $131,722 into a Promissory Note with a three year term that accrues interest at 5% per annum. The note provides for interest only payments on the first and second anniversaries of the note. The note is payable in full along with any outstanding accrued interest on August 9, 2019. The Company has the right to prepay the note at any time without a premium or penalty which it did in January 2019.  The interest on this note for the three months ended March 31, 2019 and 2018 were $489 and $1,647, respectively. The Note and all accrued interest was paid in full and as of March 31, 2019, the balance is $0.

 

2018 Convertible Notes Payable

 

In April and May 2018, the Company issued convertible notes (the “2018 Convertible Notes”) payable to investors’ in the aggregate principal amount of $895,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. 2018 Convertible Notes with an aggregate principal amount of $550,000 are due on January 30, 2021, and 2018 Convertible Notes with an aggregate principal amount of $345,000 are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the fourth quarter of 2018, three note holders converted their notes with a value of $200,000 into 1,055,415 shares of common stock.  During the three months ended March 31, 2019, a note holder converted principal and accrued interest of $50,000 and $3,723, respectively, into 268,615 shares of common stock. 

 

The Company calculated a beneficial conversion feature of the 2018 Convertible Notes based on ASU 17-11 in the form of a discount of $895,000; $93,237 and $0 of this amount was amortized to interest expense during the three months ended March 31, 2019 and 2018, respectively, based on the three year term of the notes. $37,377 was also amortized for a note that was converted during the first quarter of 2019. In addition $14,870 and $0 of interest was expensed in the three months ended March 31, 2019 and 2018, respectively. 

 

Note 8 – Notes Payable and Other Related Party Transactions

 

On September 18, 2008, the Company entered into a related party transaction with Dr. Claude Ranoux.  Dr. Ranoux was then the President, Director and Chief Scientific Officer of the Company; as of the date of this filing he is a Director.  Dr. Ranoux had loaned funds to the Company to sustain its operations since January 5, 2007 (inception).  Dr. Ranoux’s total original cumulative investment as of December 31, 2008 was $96,462, as of December 31, 2017 and 2016 it is $21,888 (“the Principal Amount”) in INVO Bioscience.  On March 26, 2009, the Company and Dr. Ranoux agreed to re-write the agreement to a non-convertible note payable bearing interest at 5% per annum, the term of the note had been extended, and has been extended a couple of additional times, the current repayment date is October 31, 2018.  The Company and Dr. Ranoux can jointly decide to repay the loan earlier without prepayment penalties.  During the twelve months ended December 31, 2018 the outstanding balance of $21,888 was paid in full including all interest due, in 2017, $0 was repaid on the principal of the loan.

 

On March 5, 2009, the Company entered into a related party transaction with Kathleen Karloff, the Chief Executive Officer and a Director of the Company.  Ms. Karloff provided a short-term loan in the amount of $75,000 bearing interest at 5% per annum to the Company to fund operations.  In May 2009, Ms. Karloff loaned to the Company an additional $13,000, making her total cumulative loan $88,000 as of December 31, 2011.  This note was due on September 15, 2009, which has since been extended a few times to its current date of October 31, 2018.   During the twelve months ended December 31, 2014, Ms. Karloff loaned the Company an additional $66,000 at an interest rate of 0% by entering into a note payable agreement in satisfaction of expenses incurred by her for amounts previously advanced to the Company. This note currently has the same expiration date as the others which is October 31, 2018. During the twelve months ended December 31, 2018 $91,257 was paid against the principal of the loan, in 2017, $0 was repaid on the principal of the loan. The principal balances of the loan was $62,743 and $154,000 as of December 31 2018 and 2017 respectively.   The related interest for the twelve months ended December 31, 2018 and 2017 was $15,278 and $4,400 respectively.  During the three months ended March 31, 2019, the Company paid the remaining balance due Ms. Karloff in the amount of $62,743.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

(unaudited)

 

In December 2009, James Bowdring, the brother of Director Robert Bowdring invested $100,000 acquiring 666,667 shares of restricted common stock.  In April 2011, the Company issued a new short term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000.  The Note carries a 10% interest rate.  The note has a current balance of $25,000. The Q211 Note is convertible into Common Stock of the Company at a conversion price of $0.03 per share, subject to adjustments. During the three months ended March 31, 2019, the Company accrued interest in the amount of $616 on the Q211 Note.

 

In November 2011, the Company issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000.  The Q411 Note carries a 10% interest rate. The Q411 Note is convertible into Common Stock of the Company at a conversion price of $0.01 per share, subject to adjustments.  During the three months ended March 31, 2019, the Company accrued interest in the amount of $247 on the Q411 Note.

 

In May 2018, James Bowdring and his children participated in the “2018 Convertible Notes” offerings in the aggregate principal amount of $40,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. These Notes are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing.

 

The Company has been renting our corporate office from Forty Four Realty Trust which is owned by James Bowdring, the brother of Director & Acting Chief Financial Officer, Robert Bowdring since November 2012. It is a month to month rental arrangement for what the Company believes is less than the fair market real estate rental rate for comparable leases. The current rent is $600 per month, or $7,200 annually. In addition the Company purchases stationary supplies and marketing items at discounted rates from Superior Printing & Promotions which is also owned by James Bowdring and is in the same building as our corporate office. INVO Bioscience spent $778 and $234 with Superior during the first three months of 2019 and 2018, respectively.

 

Principal balances of the Related Party loans were as follows:

 

   

March 31,

2019

   

December 31,

2018

 
                 

James Bowdring Family - 2011 Notes

    35,000       35,000  
                 

James Bowdring Family – 2018 Convertible Notes

    40,000       40,000  
                 

Kathleen Karloff Note

    -       62,743  

Less discount

    (27,520

)

    (30,913 )

Total, net of discount

  $ 47,480     $ 106,830  

 

Interest expense on the Related Party loans was $1,751 and $2,792 for the three months ended March 31, 2019 and 2018, respectively.

 

Accounts payable and accrued liabilities balances include expenses reports for Ms. Karloff and Mr. Bowdring for expenses they paid for personally related to travel or normal business expenses. As of March 31, 2019 they were $1,762 and as of December 31, 2018, they were $1,676.

 

Note 9 – Stockholders’ Equity

 

Three Months Ended March 31, 2019

 

In January 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 60,000 shares of common stock with a fair value of $26,600 to service providers.

 

In February 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 268,615 shares of common stock for conversion of notes payable and accrued interest in the amount of $53,723. 

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

(unaudited)

 

Three Months Ended March 31, 2018

 

In January and March 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company sold 260,000 shares of common stock to accredited investors in a private placement for cash of $47,000.

 

In January 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,200,000 shares of common stock with a fair value of $138,000 to management and board members.

 

In January and March 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 352,326 shares of common stock with a fair value of $43,664 to service providers.

 

Note 10 – Stock Options and Warrants

 

As of March 31, 2019 and December 31, 2018, the Company does not have any outstanding or committed and unissued stock options or warrants.

 

Note 11 – Income Taxes

 

The Company has adopted ASC 740-10, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

 

The Company’s total deferred tax liabilities, deferred tax assets and deferred tax asset valuation allowances at March 31, 2019 and December 31, 2018 are as follows: 

 

   

March 31, 2019

   

December 31,

2018

 

Total deferred tax assets

  $ 4,240,000     $ 4,124,000  

Less valuation allowance

    (4,240,000

)

    (4,124,000

)

Total deferred tax liabilities

    -       -  

Net deferred tax asset (liability)

  $ -     $ -  

 

Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which is uncertain.  Those amounts are therefore presented on the Company’s balance sheets as a non-current asset.  Utilization of the net operating loss carry forwards may be subject to substantial annual limitations, which may result in the expiration of net operating loss carry forwards before utilization.

 

Note 12 – Commitments and Contingencies

 

A)

Operating Leases

 

In November 2012, INVO Bioscience entered into a month-to-month rental agreement with Four Forty Realty Trust with for the space it requires.  Four Forty Realty Trust is owned by investor James Bowdring, the brother of Director & Acting Chief Financial Officer Robert Bowdring. The annual rent under the agreement is $7,200 annually.

 

B)

Litigation

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

 (unaudited)

 

There has been no change in the status of the litigation INVO Bioscience, Inc., and two of its directors have been involved in since 2010, defending litigation brought by investors in an alleged predecessor of INVO Bioscience.  On March 24, 2010, INVO Bioscience, Inc. and its corporate affiliate, Bio X Cell, Inc., Claude Ranoux, and Kathleen Karloff were served an Amended Complaint, the original of which was filed on December 31, 2009 at the Suffolk Superior Court Business Litigation Session by two terminated employees of Medelle Corporation (also named as a co-defendant but no longer active), who are also attorneys, and a former investor in and creditor of Medelle.  These plaintiffs allege various claims of wrongdoing relating to the sale of assets of Medelle to Dr. Ranoux.  Plaintiffs claim that Dr. Ranoux, Ms. Karloff, and Medelle (and therefore INVO Bioscience as an alleged successor corporation) violated alleged duties owed to plaintiffs in connection with the sale.  Separate claims were also alleged against INVO Bioscience.

 

Dr. Ranoux, Ms. Karloff, and INVO Bioscience have challenged these allegations, which they believe are baseless.  The transfer of the assets of Medelle was professionally handled by an independent third party, after approval by the Medelle Board of Directors, representing a majority of its shareholders.  Medelle’s Board voted to proceed with an assignment for the benefit of creditors (AFBC) and gave complete authority to the President & CEO at that time (neither Dr. Ranoux nor Ms. Karloff) to work with the third-party assignee and to get the best possible price for those assets.  The third party was responsible for notifying all the appropriate parties and for filing notices in various professional publications and newspapers of Medelle’s intention to sell its assets.  The third party also contacted numerous large medical device and bio-pharma companies to learn if they would be interested in acquiring the assets.  After a private sale was deemed unlikely, the assignee of the assets elected to proceed with a sealed-bid auction of the assets.  On the day of the auction, Dr. Ranoux submitted the only bid and was awarded the assets, upon full payment. 

 

During 2010, Dr. Ranoux, Ms. Karloff, and INVO Bioscience filed Motions to Dismiss as to all claims, pursuant to M.R.Civ. P. 12(b)(6).  In a written Decision rendered on November 12, 2010, the judge dismissed all claims against INVO, Bio X Cell, and Ms. Karloff, and also dismissed the claims against Dr. Ranoux alleging civil conspiracy and breach of M.G.L. c. 93A.  The judge denied Dr. Ranoux’s motion to dismiss the remaining breach of fiduciary duty and fraud claims.  The plaintiffs allege in their Amended Complaint that Dr. Ranoux committed fraud by failing to inform them of the details of the Medelle auction. 

 

The claims against Dr. Ranoux that survived the November 2010 dismissal order were submitted to binding arbitration.  On February 15, 2013, the mutually-agreed arbitrator ruled in favor of Dr. Ranoux. The award held that Dr. Ranoux did not withhold information about the auction of Medelle’s assets and expressed doubt that the plaintiffs would have invested the resources necessary to make a beneficial use of the assets.  The arbitrator’s award then was confirmed by the Superior Court on August 21, 2013.  The Superior Court’s confirmation of the award was affirmed on appeal on October 20, 2013 by the Massachusetts Appeals Court.  The Massachusetts Supreme Judicial Court then denied further appellate review.  

 

On October 18, 2016, following motions and argument, the Superior Court issued a memorandum of decision and order denying plaintiffs’ motion for entry of default judgment and assessment of damages against Medelle and allowed the motion of INVO Bioscience, Bio X Cell, and Ms. Karloff for entry of final judgment of dismissal.  The foregoing order was converted to a final judgment dismissing all claims against all defendants and entered on the docket on October 27, 2016.

 

On November 28, 2016, plaintiffs filed an amended notice of appeal from the Superior Court’s decision of October 17, 2016 and the subsequent judgment entered on October 27, 2016.  The appeal further challenges the order of dismissal from November, 2010.  Plaintiffs did not appeal from the dismissal of the claims against Ms. Karloff, so the judgment in her favor is now final, leaving claims against INVO Bioscience, Bio X Cell, Medelle, and Dr. Ranoux.

 

INVO Bioscience and Bio X Cell intend a vigorous opposition to the current appeal, consistent with their previous positions that no breach of duty occurred in the sale of Medelle’s assets. It is assumed that Dr. Ranoux will oppose the appeal as well.

 

Outside of the above-mentioned litigation, neither INVO Bioscience nor Bio X Cell, our wholly-owned subsidiary, either directly or indirectly, are involved in any lawsuit outside the ordinary course of business, the disposition of which would have a material effect upon either our results of operation, financial position, or cash flows.

 

C)

Employee Agreements

 

The Company is in the process of writing employment agreements for its current officers, executives and employees of the Company.

 

D)

Consulting Agreements

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

(unaudited)

 

The Company has a verbal agreement beginning in March, 2013 with its former CFO, Robert Bowdring, who is currently a Director & Acting Chief Financial Officer, to assist where necessary in the financial and administrative areas of the Company for compensation to be equivalent to the others working in the organization.

 

Note 13 – Contracts with Customers

 

We have adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2018 using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenues for 2018 are reported under ASC 606, while prior period amounts are not adjusted and continue to be reported under ASC 605, Revenue Recognition.

 

Revenues for products, including: INVOcell®, INVO TM Retention System, and INVO Microscope Holding Block are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenues from consignment are recognized when the medical device is shipped from the Consignor to the customer.

 

In January, 2019 we announced a U.S. license and distribution agreement with Ferring International Center S.A. (“Ferring”) and as a result took a significant step to strengthen the Company that we believe will allow us to implement our overall business plan. We believe that this strategic partnership with a strong reproductive organization such as Ferring Pharmaceuticals will provide us with the necessary sales and marketing resources within the United States to expand the market and help reach all of those couples not receiving reproductive treatments today.  The agreement calls for the issuance of an initial upfront payment of $5 million which we received upon the signing of the agreement and then subsequent licensing fee payment of $3,000,000 that will provide us with a source of non-dilutive financing to execute our plan. Under the terms of the agreement we can pursue developing international markets and as well as partnering and opening INVO-only reproductive centers within the U.S. market. We believe this major milestone and agreement is a critical step that allows the Company to implement its mission of expanding access to care in the fertility marketplace.

 

Under the terms of the Distribution Agreement, Ferring completed its obligation to make an initial payment to the Company of $5,000,000 upon completion of the required closing conditions, including executed agreements from all current manufacturers of the Licensed Product that upon a material supply default by the Company, Ferring can assume a direct purchase relationship with such manufacturers. Ferring is obligated to make a second payment to the Company of $3,000,000 provided that the Company is successful in obtaining a five (5) day label enhancement from the FDA for the current incubation period for the Licensed Product at least three (3) years prior to the expiration of the term of the license for the Licensed Product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, the Company entered into a separate Distribution Agreement.  The Distribution Agreement has an initial term expiring on December 31, 2025 and at the end of the initial term it may be terminated by the Company if Ferring fails to generate specified minimum revenues to the Company from the sale of the Licensed Product during the final two years of the initial term.

 

The Ferring license was deemed to be a functional licenses that provide customers with a “right to access” to our intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. During the quarter ended March 31, 2019, the Company recognized $178,572 related to the Ferring license agreement.  

 

As of March 31, 2019 and December 31, 2018, the Company had deferred revenues of $4,840,323 and $18,895, respectfully.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

(unaudited)

 

Sources of Revenue

 

We have identified the following revenues disaggregated by revenue source:

 

 

 

Domestic Physicians  – direct sales of products concluded in January 2019 

 

Domestic Distributor - sales to Ferring who then sells to physicians

 

Domestic Licensing fee

 

 

 

 

 

International Distributors  – direct sales of products.

 

For the three months ended March 31, 2019 and 2018 the source of revenue was derived from:

 

   

March 31,

2019

   

March 31,

2018

 
                 

Domestic Physicians

  $ 10,860     $ 104,140  
                 

Domestic Licensing & Distribution Fee

    178,572       -  
                 

Total revenue

  $ 189,432     $ 104,140  

 

Contract Balances

 

We incur agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate.

 

Warranty

 

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

 

Commissions and Contract Costs

 

We do not use or offer sales commissions of any type at this time. We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement.

 

Practical Expedients

 

Our payment terms for sales direct to customers and distributors are substantially less than the one year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

 

 

INVO BIOSCIENCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

 (unaudited)

 

Shipping and Handling Charges

 

Fees charged to customers for shipping and handling of products are included as an offset to the costs for shipping and handling of products included as a component of cost of products.

 

Taxes Collected from Customers

 

As our products are used in another service and are exempt, to this point we have not collected taxes. If we were to collect taxes they would be on the value of transaction revenue and would be excluded from product revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities.

 

Effective Date and Transition Disclosures

 

Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements, and is not expected to have a material impact in future periods.

 

Note 14 – Subsequent Events

 

On April 24, 2019, the Company issued 800,000 shares of common stock in connection with the conversion of a note payable in the principal amount of $160,000.

 

The Company has evaluated subsequent events through the date the financial statements were released and there were no others.

 

 

Item 2.       Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Statements made in this Quarterly Report on Form 10-Q, including without limitation this Management’s Discussion and Analysis of Financial Condition and Results of Operations, other than statements of historical information, are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These forward-looking statements may sometimes be identified by such words as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue” or similar words.  We believe that it is important to communicate our future expectations to investors.  However, these forward-looking statements involve many risks and uncertainties including those referred to herein and in our Annual Report on Form 10-K for the year ended December 31, 2018.  Our actual results could differ materially from those indicated in such forward-looking statements as a result of certain factors.  We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results.

 

Overview

 

INVO Bioscience’s mission is to increase access to care and expand fertility treatment and patient care across the globe. We have developed the INVOcell device and procedure, the first Intravaginal Culture (IVC) system granted FDA clearance in the United States, in hope of providing millions of infertile couples across the country access to this new infertility treatment. This novel device and procedure provides a more natural, safe, effective and economical fertility treatment compared to current infertility treatments, including in-vitro fertilization (“IVF”) and intrauterine insemination (“IUI”). The patented INVOcell device is used for the incubation of eggs and sperm during fertilization and early embryo development. Unlike conventional infertility treatments such as IVF where the eggs and sperm develop into embryos in a laboratory incubator, the INVOcell utilizes the women’s vagina as an incubator to support a more natural fertilization and embryo development environment. This novel device promotes in vivo conception and early embryo development.

 

In both current utilization of the INVOcell and in clinical studies, the INVO Procedure has proven to have equivalent pregnancy success rates as the traditional assisted reproductive technique IVF. Additionally, the psychological benefits of the potential mother’s participation in fertilization and early embryo development by vaginal incubation are incomparable to traditional IVF treatment. This new technique offers to patients a more natural and personalized way to achieve pregnancy and is simple enough to be performed in an appropriately trained physician’s office or in a satellite facility of an IVF center.

 

For many couples struggling with infertility, access to treatment is often not available. Financial challenges, limited availability of specialized medical care, religious, social and cultural roadblocks can prevent these hopeful couples from realizing their dream to have a baby. There are many benefits to the INVO Procedure, including:

 

• Reduces the risk of errors of a wrong embryo transfers since the embryos are never far from the woman.

• Reduces the worry of leaving embryos in an incubator where mix-ups have been known to occur.

• Promotes greater involvement by couples in the treatment and conception.

• Creates a more natural and environmentally stable incubation than traditional IVF incubation in a laboratory.

• Reduces the worry of leaving embryos in an incubator where mix-ups have been known to occur.

• Requires fewer office visits for the couples.

 

In January 2019, Distribution Agreement with Ferring and as a result took a significant step to strengthen the Company that we believe will allow us to implement our overall business plan. We believe that this strategic partnership with a strong reproductive organization such as Ferring Pharmaceuticals will provide us with the necessary sales and marketing resources within the United States to expand the market and help reach all of those couples not receiving reproductive treatments today.  The agreement calls for the issuance of an initial upfront payment of $5 million which we received upon the signing of the agreement and then subsequent licensing fee payment of $3,000,000 that will provide us with a source of non-dilutive financing to execute our plan. Under the terms of the agreement we can pursue developing international markets and as well as partnering and opening up to five INVO-only reproductive centers within the U.S. market. We believe this major milestone and agreement is a critical step that allows the Company to implement its mission of expanding access to care in the fertility marketplace.

 

 

Prior to the Ferring agreement, one of the largest challenges that INVO Bioscience faced was raising the appropriate capital to implement its business plan while opening the US market as well as pursuing other opportunities across the globe. With our new Distribution Agreement with Ferring we feel we have eliminated that challenge for the foreseeable future. We believe we have the appropriate funding to execute our business plan over the next 18 months.

 

We anticipate that we will experience significant quarterly fluctuations in our sales and revenues as a result of the Company’s efforts to expand the sales of the INVO technology across the United States and into new markets.  Operating results will depend upon the continued rollout of the INVOcell device across the U.S. by Ferring as well the training of international physicians and their staffs’ on the INVO procedure. In the current year our operating results will be heavily dependent on Ferring’s ability to penetrate the U.S. markets.

 

For the three months ended March 31, 2019 INVO Bioscience continued for a fifth consecutive quarter with revenue over $100,000. The Company continues to establish a market in the United States for its patented INVO procedure & INVOcell device which is now being offered by clinics in 19 states and as far west as Hawaii. We anticipate Ferring will be able to significantly expand our offering with is sales and marketing resources in the months and years ahead.

 

This first quarter of 2019 was a transition period for INVO and Ferring as a result of entering into the Distribution Agreement. We had shipped some product in the fourth quarter of 2018 to allow Ferring to meet initial customer demand after the signing of the agreement. However during the first quarter the Company worked closely with Ferring to develop new packaging, labeling and branding for the products. As a result of this re-packaging effort, our actual product revenue was low in the first quarter of 2019.   The production of the new Ferring packaged INVOcell was completed in April and the Company has commenced shipments to Ferring beginning in the second quarter. The Company currently has a backlog of orders for Ferring and anticipates it will have a significant increase in revenue during the second quarter of 2019.

 

The Company received a $5 million license fee from Ferring in exchange for their right to market and distribute INVO products across the United States. The license fee will be accounted for over the course of the seven year agreement, we will recognize $178,000 per quarter in revenue.

 

Now that the Company has received funding it has started to execute a number of additional strategic initiatives in its business plan. Currently the Company approximately $350,000 per quarter to fund its operations and we plan to continue to control our spending.  Our quarterly use of cash will increase as we expand our team and use cash to pay our key vendors versus our shares of our common stock as we have in the past. During the quarter we expanded our new product development efforts and worked with Ferring on new packaging and labeling. In addition our new COO and VP of Product Development started to travel internationally to initiate partnership and distribution discussions with potential organizations in the Middle East, Europe and Asia. We have engaged additional investor relations resources and started to improve some of our internal systems.

 

Additionally, the Company has worked to improve its balance sheet and settle long overdue liabilities with vendors, current and former employees. Over the past 12 months beginning March 31, 2018 we reduced our notes payable from $350,000 down to $35,000, our accrued compensation from $4,037,000 down to $932,000. We see 2019 as the turning point to build INVO Bioscience into a global reproductive organization.

 

Our registered independent certified public accountants have stated in their report dated April 16, 2019, filed with the Company’s Annual Report on Form 10-K that the Company has a generated negative cash outflows from operating activities, experienced recurring net operating losses, and was dependent on securing additional equity or debt financing to support its business efforts. We continue and expect to continue to generate negative cash outflows from operating activities during 2019 as the business continues to grow. As a result of the execution of the Distribution Agreement with Ferring we now believe we have sufficient capital for at least the subsequent 18 months and will be able to grow the overall business more rapidly, moving it toward the goal of generating positive cash flow from operations, although we make no assurances in this regard.   

 

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of financial condition and results of operations are based upon the unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles as recognized in the United States of America. The preparation of these financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and disclosure of contingent assets and liabilities.  Our estimates include those related to revenue recognition, the valuation of inventory, and valuation of deferred tax assets and liabilities, useful lives of intangible assets, warranty obligations and accruals.  We base our estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances.  Actual results may differ from these estimates under different assumptions or conditions.  For a complete description of accounting policies, see Note 1 to our financial statements included in our Form 10K for the year ended December 31, 2018.  There were no significant changes in critical accounting estimates.

 

Results of Operations

 

Three months ended March 31, 2019, compared to the three months ended March 31, 2018

 

Net Sales and Revenues

 

Revenue for the three months ended March 31, 2019, was $189,432 compared to $104,140 for the same three month period in 2018, an increase of $85,292 or 82%.  The increase was the result of recognizing 3.6%of the Ferring seven year U.S. exclusive licensing & distribution fee that was recorded in January 2019 upon the execution of the agreement between the two companies.

 

Gross Margin

 

The gross margin reported for the first quarter ended March 31, 2019 was 94% or $178,454 compared to 86% or $89,716 for the three months ended March 31, 2018. The increase in gross margin was related to the 2019 licensing fee that did not have any cost of sales expenses associated with it. The cost of sales recognized during the first quarter of 2019 were attributed to the small volume of product shipments early in the quarter and the expenses related to the development of the new Ferring packaging and labeling.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the three months ended March 31, 2019 were $527,565 as compared to $229,999 for the three months ended March 31, 2018, an increase of $297,566 or 129%.  The increase in SG&A during the first quarter of 2019 compared to the first quarter of 2018 was the result of salaries and benefits being paid to the existing and new staff and additional supporting resources along with higher amortization of director’s fees due to the increased stock price in the market. New expenses in 2019 included initial site development work for INVO only centers, increased U.S. and international travel in starting to develop partnerships and business insurances. We also incurred higher legal expenses related to the Ferring agreements and the preparation of the S-1 filing along with higher costs associated with increased investor awareness efforts.

 

Interest Expense and Financing Fees

 

During the three month period ended March 31, 2019 we incurred $109,459 in interest expense, an increase of $105,019 compared to $4,440 in the three-month period ended March 31, 2018. The primary reason for the increase in 2019 was the amortization of discount on the 2018 Convertible Notes Payable in the amount of $93,237 along with $13,982 of interest for the same notes. In the first three months of 2019 we had $2,240 of note payable interest compared to note payable interest of $4,440 the first quarter of 2018.

 

Net Loss

 

For the reasons stated above, the Company had a net loss of $458,570 for the three months ended March 31, 2019, an increase of $313,847 compared to a net loss of $144,723 for the three months ended March 31, 2018.

   

 

Liquidity and Capital Resources

 

Net cash as of March 31, 2019, was $3,057,466, or $2,845,233 higher than net cash of $212,243 at December 31, 2018.

 

The Company believes that its cash on hand is adequate to meet the Company’s current liquidity requirements for at least the next fifteen months.  

 

Net cash generated by operating activities was $3,088,088 for the three months ended March 31, 2019, compared to net cash used by operating activities of $37,353 for the three months ended March 31, 2018.  The increase in net cash was primarily due to the $4,821,428 increase in deferred revenue as a result of the initial exclusive license and distribution agreement fee received by the Company in January 2019 upon the signing of the agreements. Adding to this increase were the decreases in accounts receivable of $151,182 and prepaid expenses of $22,758 and increase in accounts payable and accrued expenses of $20,249. These increases were offset by reductions in accrued compensation of $1,582,595 along with an increase in inventory of $8,172 as we purchased new packaging per the Ferring Agreement. In addition we increased spending on strategic initiatives as outlined in Selling, General and Administrative Expenses above.

  

The Company started developing and purchasing molds for the next generation of the INVOcell using $48,400 during the first three months of 2019. No cash was used during the first three months of 2018 in investing activities.

 

Cash used in financing activities was $194,465 during the three months ended March 31, 2019. This was used to pay off principle note payments for both related and non-related party loans during the period. 

 

Our registered independent certified public accountants have stated in their report dated April 16, 2019, filed with the Company’s Annual Report on Form 10-K that the Company has a generated negative cash outflows from operating activities, experienced recurring net operating losses, and is dependent on securing additional equity and debt financing to support its business efforts.  These factors among others may raise substantial doubt about our ability to continue as a going concern.

 

Our existing cash resources, and cash flow from operations will provide adequate resources to fully support our operations during fiscal 2019 and beyond. The payment under the Distribution Agreement in this first quarter of 2019 provided us with the strategic funding necessary to execute our business plan over the next 12 to 24 months.

 

Critical Accounting Policies and Estimates

 

There have been no material changes in our critical accounting policies or critical accounting estimates since December 31, 2018. For further discussion of our accounting policies see the “Summary of Significant Accounting Policies” in the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 as well as the notes to the financial statements contained in this Quarterly Report on Form 10-Q.

 

The accounting policies that reflect our more significant estimates, judgments and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ACS 606, when a customer obtains control of promised goods and is recognized at an amount that reflects the consideration expected to be received in exchange for such goods and collectability of the resulting receivable is reasonably assured.

 

Intangible Assets

 

The Company’s intangible assets consist of its INVOcell and INVO process patents The Company amortizes its intangible assets with definitive lives over their useful lives, which range up to 20 years, based on the time period the Company expects to receive the economic benefit from these assets. No impairment charge was recorded during the three months period ended March 31, 2019 or 2018.

 

The Company continually assesses whether events or changes in circumstances have occurred that may warrant revision of the estimated useful lives of its intangible and indefinite-lived assets or whether the remaining balances of those assets should be evaluated for possible impairment. There were no changes in the carrying value of intangible and indefinite-lived assets during the three months ended March 31, 2019.

 

 

Impairment of Long-Lived Assets

 

The Company’s long-lived assets are its patents which are subject to amortization. The Company evaluates long-lived assets for recoverability whenever events or changes in circumstances indicate that an asset may have been impaired. In evaluating an asset for recoverability, the Company estimates the future cash flow expected to result from the use of the asset and eventual disposition. If the expected future undiscounted cash flow is less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying amount over the fair value of the asset, is recognized.

 

The Company continually assesses whether events or changes in circumstances have occurred that may warrant revision of the estimated useful lives of its intangible and indefinite-lived assets or whether the remaining balances of those assets should be evaluated for possible impairment. There were no changes in the carrying value of intangible and indefinite-lived assets during the three months ended March 31, 2019.

 

Allowance for Doubtful Accounts Receivable

 

The Company performs ongoing credit evaluations of our customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by our review of their current credit information. We continuously monitor collections and payments from our customers and maintain a provision for estimated credit losses based upon our historical experience and any specific customer collection issues that we have identified. While such credit losses have historically been minimal, within our expectations and the provisions established, we cannot guarantee that we will continue to experience the same credit loss rates that we have in the past. A significant change in the liquidity or financial position of any of our significant customers could have a material adverse effect on the collectability of our accounts receivable and our future operating results.

 

Income Taxes

 

As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax provision (benefit) in each of the jurisdictions in which we operate. This process involves estimating our current income tax provision (benefit) together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheets. We regularly evaluate our ability to recover the reported amount of our deferred income taxes considering several factors, including our estimate of the likelihood of the Company generating sufficient taxable income in future years during the period over which temporary differences reverse.

 

Recent Accounting Pronouncements

 

For information regarding recent accounting pronouncements and their effect on the Company, see “Recent Accounting Pronouncements” in Note 2 of the Unaudited Notes to Unaudited Condensed Consolidated Financial Statements contained herein

 

Forward Looking Statements

 

The statements contained in this Quarterly Report on Form 10-Q which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, the commercialization of our technology, regulatory approvals, our development of new technologies, the adequacy of our ability to develop current financing sources to fund our operations, our growth initiatives, and the strength of our intellectual property portfolio. These forward-looking statements may be identified by the use of words such as “plans”, “intends,” “may,” “could,” “expect,” “estimate,” “anticipate,” “continue” or similar terms, though not all forward-looking statements contain such words. The actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices from customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to comply with our debt obligations, our ability to deleverage our balance sheet, and seasonality, as well as the uncertainties set forth in the Company’s Annual Report on Form 10-K, filed on April 16, 2019, including the risk factors contained in Item 1A, and from time to time in the Company’s other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

Item 3.       Quantitative and Qualitative Disclosures about Market Risks

 

Not Applicable

 

Item 4.       Controls and Procedures

 

Item 4a.     Evaluation of Disclosure Controls and Procedures

 

The Company’s management, under the supervision and with the participation of the Company’s Chief Executive Officer and Acting Chief Financial (and principal accounting) Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act) as of March 31 2019, the end of the fiscal period covered by this Form 10Q.  We maintain disclosure controls and procedures that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.   Based upon that evaluation and the identification of the material weakness in the Company’s internal control over financial reporting as of December 31, 2018 (described below) which has not been remediated as of the end of the period covered by this Quarterly Report, our Chief Executive Officer and Acting Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were ineffective as of the end of the period covered by this Quarterly Report. 

 

Because of the Company’s limited resources and limited number of employees, management concluded that, as of March 31, 2019, our internal control over financial reporting is not effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

 

To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of legal and accounting professionals. The Company is taking steps to create effective procedures and controls throughout the organization.  The Company is in the process of establishing procedures and segregating duties where it can.  It has implemented a new accounting system, has outsourced its accounts payable function, implemented an approval processes, created a number of policies, reporting processes, a standard customer contract and has introduced an employee manual.  We will continue to monitor our disclosure controls and procedures and will address areas of potential concern.  As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.

 

As a result of the infusion of cash into the Company with the closing of the Distribution Agreement with Ferring we will be taking steps to enhance our internal and disclosure controls.

 

Our management, including our Chief Executive Officer and Acting Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud.  A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.  Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.  These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.  Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.  The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.  Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.  Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

Item 4b.     Changes in Internal Control over Financial Reporting

 

There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II. OTHER INFORMATION

 

Item 1.      Legal Proceedings

 

As outlined in the Annual Report on Form 10K filed on April 16, 2019, there has been no change in the status in the suit INVO Bioscience, Inc., and two of its directors have been involved in since 2010, defending litigation brought by investors in an alleged predecessor of INVO Bioscience.  On March 24, 2010, INVO Bioscience, Inc. and its corporate affiliate, Bio X Cell, Inc., Claude Ranoux, and Kathleen Karloff were served an Amended Complaint, the original of which was filed on December 31, 2009 at the Suffolk Superior Court Business Litigation Session by two terminated employees of Medelle Corporation (also named as a co-defendant but no longer active), who are also attorneys, and a former investor in and creditor of Medelle.  These plaintiffs allege various claims of wrongdoing relating to the sale of assets of Medelle to Dr. Ranoux.  Plaintiffs claim that Dr. Ranoux, Ms. Karloff, and Medelle (and therefore INVO Bioscience as an alleged successor corporation) violated alleged duties owed to plaintiffs in connection with the sale.  Separate claims were also alleged against INVO Bioscience.

 

Dr. Ranoux, Ms. Karloff, and INVO Bioscience have challenged these allegations, which they believe are baseless.  The transfer of the assets of Medelle was professionally handled by an independent third party, after approval by the Medelle Board of Directors, representing a majority of its shareholders.  Medelle’s Board voted to proceed with an assignment for the benefit of creditors (AFBC) and gave complete authority to the President & CEO at that time (neither Dr. Ranoux nor Ms. Karloff) to work with the third-party assignee and to get the best possible price for those assets.  The third party was responsible for notifying all the appropriate parties and for filing notices in various professional publications and newspapers of Medelle’s intention to sell its assets.  The third party also contacted numerous large medical device and bio-pharma companies to learn if they would be interested in acquiring the assets.  After a private sale was deemed unlikely, the assignee of the assets elected to proceed with a sealed-bid auction of the assets.  On the day of the auction, Dr. Ranoux submitted the only bid and was awarded the assets, upon full payment. 

 

During 2010, Dr. Ranoux, Ms. Karloff, and INVO Bioscience filed Motions to Dismiss as to all claims, pursuant to M.R.Civ. P. 12(b)(6).  In a written Decision rendered on November 12, 2010, the judge dismissed all claims against INVO, Bio X Cell, and Ms. Karloff, and also dismissed the claims against Dr. Ranoux alleging civil conspiracy and breach of M.G.L. c. 93A.  The judge denied Dr. Ranoux’s motion to dismiss the remaining breach of fiduciary duty and fraud claims.  The plaintiffs allege in their Amended Complaint that Dr. Ranoux committed fraud by failing to inform them of the details of the Medelle auction. 

 

The claims against Dr. Ranoux that survived the November 2010 dismissal order were submitted to binding arbitration.  On February 15, 2013, the mutually-agreed arbitrator ruled in favor of Dr. Ranoux. The award held that Dr. Ranoux did not withhold information about the auction of Medelle’s assets and expressed doubt that the plaintiffs would have invested the resources necessary to make a beneficial use of the assets.  The arbitrator’s award then was confirmed by the Superior Court on August 21, 2013.  The Superior Court’s confirmation of the award was affirmed on appeal on October 20, 2013 by the Massachusetts Appeals Court.  The Massachusetts Supreme Judicial Court then denied further appellate review.  

 

On October 18, 2016, following motions and argument, the Superior Court issued a memorandum of decision and order denying plaintiffs’ motion for entry of default judgment and assessment of damages against Medelle and allowed the motion of INVO Bioscience, Bio X Cell, and Ms. Karloff for entry of final judgment of dismissal.  The foregoing order was converted to a final judgment dismissing all claims against all defendants and entered on the docket on October 27, 2016.

 

On November 28, 2016, plaintiffs filed an amended notice of appeal from the Superior Court’s decision of October 17, 2016 and the subsequent judgment entered on October 27, 2016.  The appeal further challenges the order of dismissal from November, 2010.  Plaintiffs did not appeal from the dismissal of the claims against Ms. Karloff, so the judgment in her favor is now final, leaving claims against INVO Bioscience, Bio X Cell, Medelle, and Dr. Ranoux.

 

INVO Bioscience and Bio X Cell intend a vigorous opposition to the current appeal, consistent with their previous positions that no breach of duty occurred in the sale of Medelle’s assets. It is assumed that Dr. Ranoux will oppose the appeal as well.

 

Outside of the above-mentioned litigation, neither INVO Bioscience nor Bio X Cell, our wholly-owned subsidiary, either directly or indirectly, are involved in any lawsuit outside the ordinary course of business, the disposition of which would have a material effect upon either our results of operation, financial position, or cash flows.

 

 

Item 1A.   Risk Factors

 

You should carefully review and consider the information regarding certain factors that could materially affect our business, financial condition or future results set forth under “Item 1A.  Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed on April 16, 2019 with the SEC.  There have been no material changes from the factors disclosed in our 2018 Annual Report on Form 10-K, although we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the Securities and Exchange Commission.

 

Item 2.      Unregistered Issuance of Equity Securities and Use of Proceeds

 

During the period covered by this Report, we issued 268,615 shares of common stock for the conversion of a convertible note and accrued interest, and 60,000 shares of common stock to service providers for services. We claimed the exemption from registration set forth in Section 4(a)(2) of the Securities Act and the rules there under, as private transactions not involving a public distribution.  The facts we relied upon to claim the exemption include: (i) all represented that they acquired the shares from the Company for investment and not with a view to distribution to the public; (ii) each certificate issued for unregistered securities contains a legend stating that the securities have not been registered under the Securities Act and setting forth the restrictions on the transferability and the sale of the securities; (iii) most represented that they are accredited investors and all are familiar with our business activities; and (iv) all given full and complete access to any corporate information they requested.

 

Item 3.      Defaults Upon Senior Securities

 

None.

 

Item 4.      Reserved

 

Item 5.      Other Information

 

None.

 

Item 6.      Exhibits

 

31.1

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

32

Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

101

The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018, (ii) Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018, (iii) Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018, and (iv) Notes to Consolidated Financial Statements.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on May 15, 2019.

 

 

INVO Bioscience, Inc.

 

 

 

 

 

Date:  May 15, 2019

By:

/s/Kathleen Karloff                     

 

 

 

Kathleen Karloff, Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

Date:  May 15, 2019

By:

/s/ Robert J. Bowdring           

 

 

 

Robert J. Bowdring, Treasurer and

 

 

 

Acting Chief Financial Officer

(Acting Principal Financial and Accounting Officer)

 

 

 

 

 

EXHIBIT INDEX

 

31.1

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

32

Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

101

The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018, (ii) Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018, (iii) Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018, and (iv) Notes to Consolidated Financial Statements

 

 

 

 

 

 

25